Literature DB >> 8563771

A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.

D Marez1, N Sabbagh, M Legrand, J M Lo-Guidice, P Boone, F Broly.   

Abstract

A novel loss-of function allele of the CYP2D6 gene was characterized in a PM individual using exon-by-exon PCR-SSCP analysis. This allele, we termed CYP2D6(F), harbours four mutations including a new mutation (D6-F) which abolishes the splice acceptor site of the 1st intron and results in a premature stop codon. DNA samples from a large population of healthy unrelated volunteers were tested for D6-F using a PCR-assay we developed for the specific identification of the mutation in genomic DNA. The prevalence of D6-F was very low. However, its identification combined with that of the previously reported gene inactivating mutations would further increase the phenotype prediction rate by genotyping.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563771     DOI: 10.1097/00008571-199510000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  11 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  Identification of CYP2D6 impaired functional alleles in Mexican Americans.

Authors:  Huai-Rong Luo; Andrea Gaedigk; Vasileios Aloumanis; Yu-Jui Yvonne Wan
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

Review 4.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

5.  An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

Authors:  D Marez; M Legrand; N Sabbagh; J M Lo-Guidice; P Boone; F Broly
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

6.  The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.

Authors:  Benjamin J Davies; Janet K Coller; Heather M James; Andrew A Somogyi; John D Horowitz; Benedetta C Sallustio
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Intronic polymorphisms of cytochromes P450.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim
Journal:  Hum Genomics       Date:  2010-08       Impact factor: 4.639

9.  Pharmacogenomics: what is next?

Authors:  Julia di Iulio; Margalida Rotger
Journal:  Front Pharmacol       Date:  2012-01-13       Impact factor: 5.810

10.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

Authors: 
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.